Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJul 02, 2026
DataAggregated Company Financials
Companies66
  • 7D5.0%
  • 3M13.6%
  • 1Y15.3%
  • YTD-6.0%

Over the last 7 days, the Life Sciences industry has risen 5.0%, driven by gains from Thermo Fisher Scientific of 4.3%. Meanwhile, Nautilus Biotechnology actually underperformed within the industry, shrinking 22% in the last week. This takes the industry's 12 month performance to a gain of 15%. As for the next few years, earnings are expected to grow by 17% per annum.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 02 Jul 2026US$627.7bUS$151.2bUS$13.6b45x46x4.2x
Sat, 30 May 2026US$588.3bUS$150.6bUS$13.8b37.9x42.8x3.9x
Mon, 27 Apr 2026US$546.1bUS$149.0bUS$14.4b30.5x38x3.7x
Wed, 25 Mar 2026US$547.3bUS$147.8bUS$14.0b35.8x39x3.7x
Fri, 20 Feb 2026US$594.3bUS$147.7bUS$13.8b34.6x43x4x
Sun, 18 Jan 2026US$693.3bUS$145.8bUS$12.4b36.8x56.1x4.8x
Tue, 16 Dec 2025US$656.7bUS$145.8bUS$12.5b35.4x52.6x4.5x
Thu, 13 Nov 2025US$653.1bUS$145.7bUS$12.2b35.5x53.7x4.5x
Sat, 11 Oct 2025US$619.8bUS$144.3bUS$14.6b31.7x42.6x4.3x
Mon, 08 Sep 2025US$581.6bUS$144.3bUS$14.6b29.9x40x4x
Wed, 06 Aug 2025US$555.7bUS$144.0bUS$13.0b32.3x42.6x3.9x
Fri, 04 Jul 2025US$548.4bUS$142.9bUS$9.1b36.4x60.1x3.8x
Sun, 01 Jun 2025US$504.4bUS$142.9bUS$9.2b32.4x54.6x3.5x
Tue, 29 Apr 2025US$519.5bUS$142.5bUS$10.0b37.2x51.9x3.6x
Thu, 27 Mar 2025US$594.0bUS$143.0bUS$9.9b38.6x60x4.2x
Sat, 22 Feb 2025US$619.6bUS$143.3bUS$9.6b38.8x64.4x4.3x
Mon, 20 Jan 2025US$681.4bUS$142.4bUS$10.2b43.8x66.8x4.8x
Wed, 18 Dec 2024US$666.3bUS$142.3bUS$10.2b45.5x65.2x4.7x
Fri, 15 Nov 2024US$683.9bUS$142.4bUS$10.3b43.5x66.4x4.8x
Sun, 13 Oct 2024US$731.7bUS$141.8bUS$8.5b37.7x86.1x5.2x
Tue, 10 Sep 2024US$739.9bUS$141.8bUS$8.5b38.1x87.1x5.2x
Thu, 08 Aug 2024US$732.0bUS$141.6bUS$8.6b38x85.4x5.2x
Sat, 06 Jul 2024US$662.1bUS$141.3bUS$12.2b38.8x54.4x4.7x
Mon, 03 Jun 2024US$702.1bUS$141.3bUS$12.4b38.2x56.5x5x
Wed, 01 May 2024US$705.9bUS$141.5bUS$12.7b38.4x55.5x5x
Fri, 29 Mar 2024US$742.5bUS$142.1bUS$12.8b44x58x5.2x
Sun, 25 Feb 2024US$729.7bUS$142.1bUS$12.4b43.7x58.8x5.1x
Tue, 23 Jan 2024US$697.0bUS$153.8bUS$14.2b36x49.2x4.5x
Thu, 21 Dec 2023US$697.4bUS$153.7bUS$14.2b36.8x49x4.5x
Sat, 18 Nov 2023US$614.3bUS$153.9bUS$13.9b33.5x44.2x4x
Mon, 16 Oct 2023US$629.2bUS$154.6bUS$11.2b33.2x56.2x4.1x
Wed, 13 Sep 2023US$690.0bUS$154.6bUS$11.2b32.9x61.6x4.5x
Fri, 11 Aug 2023US$730.1bUS$154.7bUS$11.5b31.7x63.6x4.7x
Sun, 09 Jul 2023US$685.3bUS$152.4bUS$12.5b29.6x54.8x4.5x
Price to Earnings Ratio

54.8x


Total Market Cap: US$685.3bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.1x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 46.0x which is lower than its 3-year average PE of 56.1x.
  • The industry is trading close to its 3-year average PS ratio of 4.4x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 2.9% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.64%
Healthcare4.13%
Life Sciences5.05%
Clinical Research and Equipment5.05%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$513.334.3%
+US$7.9b		20.0%PE27.9x
DHR DanaherUS$193.722.6%
+US$3.4b		-4.3%PE37.3x
IQV IQVIA HoldingsUS$203.209.5%
+US$2.9b		23.4%PE24.5x
MTD Mettler-Toledo InternationalUS$1.30k8.1%
+US$2.0b		7.9%PE30x
TECH Bio-TechneUS$71.0020.6%
+US$1.8b		33.5%PE101x

Latest News

TMO
US$513.33
Thermo Fisher Scientific
7D
4.3%
1Y
20.0%
WST
US$365.00
West Pharmaceutical Services
7D
7.2%
1Y
65.0%
TEM
US$61.60
Tempus AI
7D
18.6%
1Y
4.1%
LFCR
US$5.27
Lifecore Biomedical
7D
-9.1%
1Y
-34.5%
Analysis Article • Jun 30

Is Now An Opportune Moment To Examine Lifecore Biomedical, Inc. (NASDAQ:LFCR)?

Lifecore Biomedical, Inc. ( NASDAQ:LFCR ), is not the largest company out there, but it received a lot of attention...
DHR
US$193.72
Danaher
7D
2.6%
1Y
-4.3%
MTD
US$1,300.38
Mettler-Toledo International
7D
8.1%
1Y
7.9%
IQV
US$203.20
IQVIA Holdings
7D
9.5%
1Y
23.4%
ILMN
US$183.89
Illumina
7D
5.0%
1Y
83.3%
Narrative Update • Jun 29

ILMN: Clinical Execution And Sector Funding Support A Cautiously Balanced Outlook

The analyst fair value estimate for Illumina has been lifted by $10 to $185, reflecting higher Street price targets and analyst expectations for stronger customer spending and margins, supported by recent research, survey feedback, and sector funding trends. Analyst Commentary Recent Street research around Illumina points to a more constructive tone, with several bullish analysts highlighting improving customer sentiment, sector funding trends, and clearer execution on the clinical side.
TECH
US$71.00
Bio-Techne
7D
20.6%
1Y
33.5%
SEER
US$1.63
Seer
7D
-3.6%
1Y
-26.2%
Narrative Update • Jun 22

SEER: Activist Bid And Buybacks Will Test Bullish Repricing Thesis

Analysts have raised their price target on Seer to $4.00, citing updated assumptions for higher revenue growth, a modestly higher discount rate, and a lower future P/E multiple as the key drivers of this revised view. What’s in the News for Seer Bradley L.
VRXA
US$1.73
Veraxa Biotech
7D
-25.0%
1Y
-83.4%
HBIO
US$6.05
Harvard Bioscience
7D
-0.5%
1Y
28.9%
Narrative Update • Jun 12

HBIO: Reverse Split And 2026 Execution Risks Will Pressure Overvalued Shares

Analysts have lifted their price target on Harvard Bioscience to $6.00, primarily reflecting the updated modeling of the recent 1-for-10 reverse stock split. What's in the News Harvard Bioscience issued earnings guidance for the second quarter of 2026, with expected revenue in a range of US$20.5 million to US$22.5 million.
CDT
US$0.52
CDT Equity
7D
-51.9%
1Y
-99.9%
BNBX
US$0.37
BNB Plus
7D
-13.3%
1Y
-92.6%
NAUT
US$1.84
Nautilus Biotechnology
7D
-22.0%
1Y
135.0%
CSBR
US$6.05
Champions Oncology
7D
-1.5%
1Y
-22.2%